1. Home
  2. IMMR vs EDIT Comparison

IMMR vs EDIT Comparison

Compare IMMR & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immersion Corporation

IMMR

Immersion Corporation

HOLD

Current Price

$6.66

Market Cap

216.7M

Sector

Technology

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.05

Market Cap

206.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMR
EDIT
Founded
1993
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
216.7M
206.0M
IPO Year
1999
2016

Fundamental Metrics

Financial Performance
Metric
IMMR
EDIT
Price
$6.66
$2.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$12.25
$4.50
AVG Volume (30 Days)
345.8K
1.9M
Earning Date
03-11-2026
03-04-2026
Dividend Yield
4.40%
N/A
EPS Growth
57.07
N/A
EPS
2.04
N/A
Revenue
$163,133,000.00
$46,383,000.00
Revenue This Year
$168.87
N/A
Revenue Next Year
$109.72
N/A
P/E Ratio
$3.34
N/A
Revenue Growth
338.21
N/A
52 Week Low
$5.65
$0.91
52 Week High
$8.80
$4.54

Technical Indicators

Market Signals
Indicator
IMMR
EDIT
Relative Strength Index (RSI) 50.44 45.03
Support Level $6.58 $1.92
Resistance Level $6.93 $2.17
Average True Range (ATR) 0.22 0.15
MACD 0.02 0.00
Stochastic Oscillator 53.39 25.29

Price Performance

Historical Comparison
IMMR
EDIT

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: